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Abstract 
Oxytocin neurones are involved in the regulation of energy balance through diverse central 
and peripheral actions, and in rats are potently activated by gavage of sweet substances. Here 
we tested the hypothesis that this activation is mediated by the central actions of insulin. We 
show that, in urethane-anesthetised rats, oxytocin cells in the supraoptic nucleus show 
prolonged activation after i.v. injections of insulin, and that this response is greater in fasted 
rats than in non-fasted rats. Vasopressin cells were also activated, but less consistently. We 
also show that this activation of oxytocin cells is independent of changes in plasma glucose 
concentration, and is completely blocked by central (i.c.v.) administration of an insulin 
receptor antagonist. Finally we replicated the previously published finding that oxytocin cells 
are activated by gavage of sweetened condensed milk, and show that this response too is 
completely blocked by central administration of an insulin receptor antagonist. We conclude 
that the response of oxytocin cells to gavage of sweetened condensed milk is mediated by the 




Insulin is widely known for its role in glucose homeostasis on peripheral tissues, but its 
central effects are not yet fully elucidated. Once secreted into the circulation, insulin is 
transported into the brain by a saturable transport mechanism (1, 2). Both exogenous insulin 
administration and glucose-stimulated insulin secretion result in a progressive increase of 
insulin in the CSF in several species, including humans (3-6).Accordingly, insulin 
concentrations in the cerebrospinal fluid (CSF) correlate with levels in plasma, but they are 
approximately 15-fold lower than plasma concentrations in fasted rats (3).  
In the brain, regions sensitive to insulin include the hypothalamus (7, 8) which 
contains insulin-responsive neurones in several nuclei (9-11). Amongst these, the insulin 
receptor (InsR) is abundantly expressed in the supraoptic nucleus (SON) (12-14) which 
exclusively contains magnocellular oxytocin and vasopressin cells, and intraperitoneal 
administration of insulin induces the expression of Fos protein in parvo- and magnocellular 
oxytocin cells of the paraventricular nucleus in rats (15). Explants of the hypothalamo-
neurohypophysial system, including the SON and its projections to the posterior pituitary, 
release oxytocin and vasopressin in response to direct application of insulin (16), and central 
administration of insulin increases peripheral secretion of oxytocin in mice, by a direct action 
on oxytocin cells (17). 
In addition to their classical roles in reproduction (18, 19), stress (20) and water 
balance (21), oxytocin and vasopressin have roles in energy homeostasis(22). Both central 
and peripheral oxytocin administration exert anorexigenic effects, increase energy 
expenditure, and induce lipolysis (23-26). Peripheral administration of both oxytocin and 
vasopressin can induce the release of insulin from the pancreas (27-30), and systemically 
administered oxytocin in humans (administered intranasally) has been reported to curb the 
meal-related increase in plasma glucose (31), and to improve β-cell responsivity and glucose 
tolerance in healthy men (32). Studies using well-validated radioimmunoassays in extracted 
plasma samples (33) indicate that patients with metabolic syndrome exhibit higher circulating 
oxytocin concentrations than normal individuals (34), and patients with diabetes have higher 
concentrations of vasopressin, and of copeptin (which is co-secreted with vasopressin) (35, 
36). 
In this study, we examine whether peripheral (i.v.) administration of insulin affects 
the electrical activity of oxytocin and vasopressin cells in the SON of urethane-anaesthetised 
rats. The effect of different feeding states, and consequently different blood glucose 
concentrations on these responses was also investigated. We investigated the role of brain 
InsR in these responses by blocking these receptors using an InsR antagonist. Finally, we 
tested whether the previously reported enhanced electrical activity of oxytocin cells in 





We used adult male Sprague–Dawley rats weighing 300-350g. The rats had ad libitum 
access to food and water and were maintained under a 12:12h light/dark cycle (lights on 
07.00h) at a room temperature of 20-21°C. In most experiments we used fasted rats to reduce 
the variability of blood glucose and gastric signals (induced by prior food consumption) 
which could affect neural activity, so in these experiments the food was removed overnight 
(~15 h). All procedures were conducted on rats under deep terminal anaesthesia in 
accordance with the UK Home Office Animals Scientific Procedures Act 1986, and a project 
licence approved by the Ethical Committee of the University of Edinburgh. 
Drugs 
Human recombinant insulin solution (cat no. I9278; Sigma-Aldrich Company Ltd., 
Dorset, UK) was diluted in 0.9% saline (B. Braun, Melsungen, Germany) at 0.25 U/100 µl. 
Glucose solution was prepared by dissolving 5% glucose (cat no. G5767; Sigma-Aldrich 
Company Ltd., Dorset, UK) in sterile distilled water. The InsR antagonist S961 (cat no. 051-
86; Phoenix Europe GmbH, Karlsruhe, Germany) was dissolved at 0.33 nmol/µl in artificial 
CSF (NaCl 138 mM, KCl 3.36 mM, NaHCO3 9.52 mM, Na2HPO4 2H2O 0.49 mM, urea 2.16 
mM, CaCl2 1.26 mM, MgCl2 6H2O 1.18 mM; pH 7.5). 
The responses of SON neurones to systemic insulin were tested by giving an i.v. bolus 
of 0.75 U/kg. To determine the effect of restoring circulating glucose content in insulin-
responsive neurones, 400µl of 5% glucose solution was given i.v. at 200 µl/min. Glucose 
concentrations were then checked 5 and 20 min later and, if lower than basal values, were 
corrected by infusing an additional 300 µl and 100 µl of 5% glucose solution, respectively. 
To investigate the role of central InsRs on insulin responses, the InsR antagonist S961 (38) 
was given into the third ventricle using a 31-gauge needle (attached behind the bipolar 
stimulating electrode) inserted through the median eminence; 1 nmole (4.8 µg) of S961 was 
injected at 1 µl/min. We chose a dose expected to be sufficient to block insulin receptors 
throughout the brain when given icv, but lower than that needed to antagonise insulin actions 
if given peripherally.  The affinity of S961 for both isoforms of the insulin receptor is close to 
that of insulin itself (38). Previous studies have reported that bilateral injections of 100 ng 
S961 into the arcuate nucleus block the effects of insulin microinjected into the arcuate 
nucleus on lumbar sympathetic nerve activity in late pregnant rats (39). Studies using the 
closely related antagonist S661, which has properties indistinguishable from those of S961, 
indicated that peripheral doses of 30 nmole/kg or more are needed to block the effects of i.v. 
administration of 30 mmole/kg insulin on blood glucose levels (38). As detailed below, the 
icv application of S961 in our hands had no significant effect on plasma glucose 
concentrations. 
Sweet condensed milk (SCM) gavage  
In fasted rats, a gavage tube was inserted orally into the stomach to deliver a total 
volume of 5 ml of SCM (Nestle, UK) diluted 50 % v/v in distilled water (40.8 kJ, 1.68g 
sugar, 0.24g fat) at 0.16 ml/min. 
In vivo electrophysiology 
Rats were briefly anaesthetised with isoflurane inhalation anaesthesia, and then 
urethane (ethyl carbamate 25% solution) was injected intraperitoneally (i.p.) at 1.25 g/kg. A 
femoral vein was cannulated for drug administration and an endotracheal tube was inserted to 
maintain the airway open, and the SON and the pituitary stalk were exposed by 
transpharyngeal surgery (40). A bipolar stimulating electrode (SNEX-200X; Clark 
Electromedical Instruments, Reading, UK) was placed on the pituitary stalk, and a glass 
microelectrode (~1 µm tip; filled with 0.9% NaCl) was lowered into the SON under visual 
control for extracellular recording. The signal was amplified using an Axonpatch 200B 
(Molecular Devices, Sunnyvale, CA, USA) connected to a HumBug 50 Hz noise eliminator 
(Quest Scientific Instruments Inc., North Vancouver, BC, Canada), and was digitalized with a 
CED-1401 laboratory interface (Cambridge Electronic Design, Cambridge, UK) connected to 
a PC running Spike2 software (version 7.20; Cambridge Electronic Design). Most recordings 
were made from single neurones; in some experiments the spike activity of two cells was 
recorded simultaneously; in these cases the spikes were discriminated and analysed offline 
using the waveform function of Spike2 software. Recordings were made between 12:00 and 
17:00 h (lights on 07.00-19.00h). Rats were tested only once with insulin. 
SON neurones were antidromically identified through stimulation of the pituitary 
stalk by matched biphasic pulses (1 ms, <1 mA peak to peak), which produce an antidromic 
spike at a constant latency (~10 ms; Fig.1A). Oxytocin cells were discriminated from 
continuous-firing vasopressin cells (Fig.1B) by the shape of the interspike interval (ISI) 
distribution (Fig.1C,D) and by their opposite response to i.v. cholecystokinin (CCK; CCK-8 
sulphated cat no. H-2080; Bachem AG, Bubendorf, Switzerland) given at 20 μg/kg, i.e. a 
transient excitation of oxytocin cells, and no effect or short inhibition of vasopressin cells 
(Fig.1E, F)(40, 41). CCK was given at the end of the experiments to identify continuously-
firing cells. 
Recording and blood sampling protocols  
Effect of i.v. insulin.  
The spontaneous spiking activity of SON neurones was recorded for 20 min (basal 
activity) and for at least 60 min after i.v. insulin. Blood samples (50 μl) were taken to 
measure glucose immediately before administration of insulin or vehicle, and 15, 30, 60, 90, 
and 120 min later. 
Effect of restoring circulating glucose content in insulin-responsive neurones. 
The basal activity of SON neurones was recorded for 20 min, and for another 30 min 
after i.v. insulin. Then, glucose was given i.v. and the spike activity recorded for further 
30min. Blood glucose concentrations were measured before insulin, 30 min later (i.e. before 
i.v. glucose), and 5 and 20 min after the first glucose injection. Only rats exhibiting in the last 
sample a blood glucose concentration within 15% of the value in the basal sample were used. 
Blockade of central InsRs 
The basal spike activity of SON neurones in fasted rats was recorded for 20 min. 
Then, S961 was given i.c.v. and spike activity recorded for 15 min. After this, insulin was 
given i.v. and the spike activity recorded for another 30 min. Blood glucose concentrations 
were measured using an Accu-Chek Aviva meter (Roche Diagnostics GmbH, Germany) 
immediately before S961 injection, 15 min later (i.e. before i.v. insulin), and 30 min after i.v. 
insulin. 
Effect of central InsR blockade on SCM-stimulated activity of oxytocin cells 
The basal spike activity of SON neurones was recorded for 20 min. Then, rats were 
injected i.c.v. with either vehicle or S961 and activity recorded for 10 min. After this, SCM 
was gavaged (over 30 min) and spike activity recorded for 1 h. Blood samples (300 μl) were 
taken immediately before the i.c.v. injection, 10 min later (i.e. before SCM gavage), and at 30 
and 60 min after the start of gavage. Blood glucose concentrations were measured 
immediately after sampling; then samples were centrifuged in EDTA-coated tubes, and 
plasma collected and stored at -80°C for insulin measurements using a rat/mouse insulin 
ELISA kit (cat. EZRMI-13K; EMD Millipore, Billerica, MA, USA). 
Hazard Functions 
Hazard function displays how the excitability of a neurone changes with the time 
subsequent to the last spike, indicating the probability of a neurone firing a spike in a given 
period. For responsive neurones in fasted rats, we constructed ISI histograms in 10-ms bins of 
the 20-min basal period and the last 30-min after insulin administration. From these, hazard 
functions (in 10-ms bins) were constructed using the formula: [hazard in bin (t, t + 10)] = 
[number of ISIs in bin (t, t + 10)]/(number of ISIs of length >t) as described by Sabatier et al. 
(42). Hazard functions plot the incidence of spikes as a proportion of the size of the residual 
tail of the ISI distribution. When plotted this way, a negative exponential distribution (the 
distribution characteristic of random events) becomes a constant ‘hazard’ proportional to the 
average firing rate. Deviation from this then becomes interpretable as periods of decreased or 
increased excitability. Consensus hazard functions were calculated from the means of hazard 
functions. 
Statistical analysis.  
Data were analysed using Graph Pad Prism 6 (GraphPad Software, CA, USA). 
Responses to insulin were analysed by comparing the mean firing rate in the 60-min after 
insulin with the (basal) firing rate over the 20-min control period. The changes were 
compared using a two-tailed Wilcoxon signed-rank test. The activity of phasic cells was 
analysed in Spike2; detection of a burst of activity was defined by spike activity lasting at 
least 5 s and containing >20 spikes followed by >5 s of spike silence between bursts. The 
mean burst duration, interburst interval and activity quotient (percentage of active time over 
the total time) over the 20-min basal and 60 min after insulin were compared using Wilcoxon 
matched-pairs signed-rank test. 
The effect of glucose on insulin-responsive cells was analysed by comparing the mean 
change in firing rate (spikes/s in 10-min bins) before and after glucose (i.e. 0–30 min vs 30–
60 min) using Wilcoxon matched-pairs signed-rank test. 
The effect of blockade of central InsRs was analysed by testing whether the mean 
change in firing rate in the 15-min after S961 injection was significantly different from 0 (i.e. 
from the basal rate), using a two-tailed Wilcoxon signed-rank test. Then the mean change in 
firing rate over 30-min after insulin was compared with the firing rate in the 15 min after 
S961 using a two-tailed Wilcoxon signed-rank test. One-way ANOVA followed by post hoc 
Bonferroni test was used to compare glucose profiles. 
The mean change in firing rate over 60-min, and glucose profiles between fasted and 
non-fasted rats were compared using two-tailed Mann Whitney test and two-way ANOVA 
followed by post hoc Bonferroni multiple comparison tests, respectively. We also compared 
the change in firing rate to determine whether different treatments affect the responses of 
SON neurones to insulin, using two-way ANOVA followed by post hoc Bonferroni test. 
The effect of prior blockade of central InsRs on SCM-induced activity was analysed 
using a two-tailed Mann Whitney test comparing the mean change in firing rate over 60 min 
between i.c.v. control- and S961-treated rats. The change in firing rate (in 10-min bins), 
blood glucose concentrations, and plasma insulin content between the two groups were 
compared using two-way ANOVA, followed by post hoc Bonferroni test. 
All data are presented as means ± S.E.M., and statistical significance was set at 




In both fasted and non-fasted rats, i.v. injections of insulin induced a prolonged 
increase in the firing rate of oxytocin cells, reaching a plateau between 30 and 60 min later. 
All cells in fasted rats and all but one in non-fasted rats increased their activity after i.v 
insulin. 
Recordings were made from 10 oxytocin cells in ten fasted rats and from 10 cells in 
nine non-fasted rats (including one double recording). In non-fasted rats, the mean (range) 
basal firing rate of 2.5(0.7-4.1)±0.4 spikes/s increased by 0.9(0.1-2.5)±0.3 spikes/s (averaged 
over the 60 min after i.v. insulin; P=0.002, Wilcoxon signed-rank test; Fig.2A,B). In fasted 
rats, oxytocin cells responded more strongly (Fig.2C): the basal firing rate of 2.4 (0.6-
4.8)±0.5 spikes/s increased by 1.6(0.4-2.7)±0.3 spikes/s (P=0.002, Wilcoxon signed-rank test; 
P=0.045 for comparison of fasted and non-fasted rats, Mann-Whitney U test). 
 
Vasopressin cells 
In six fasted rats, recordings were made from ten vasopressin cells (three phasic- and 
seven continuously firing) with a mean (range) basal firing rate of 5.0 (0.2-8.1)±0.8 spikes/s. 
After insulin, the rate increased by 1.0 (-0.2-3.5)±0.3 spikes/s over 60 min (P=0.006, 
Wilcoxon signed-rank test; Fig.2D). In the three phasic cells, insulin increased the burst 
duration from 32±11 s to 82±29 s, and decreased the interburst duration from 32±15 s to 
28±15 s; the resulting activity quotient increased from 0.5±0.2 to 0.7±0.2. The intraburst 
frequency was unchanged (basal: 3.6±0.7 spikes/s, insulin: 3.6±0.9 spikes/s). These changes 
were not statistically significant. 
In 14 non-fasted rats, recordings were made from 16 vasopressin cells (eight phasic, 
eight continuous) with a basal firing rate of 5.1(1.4-10.1)±0.7 spikes/s. After insulin, the rate 
increased by 0.7(-0.7-2.8)±0.3 spikes/s over 60 min (P=0.028, Wilcoxon signed-rank test; 
Fig. 2D). In the eight phasic cells, insulin increased the burst duration (from 73±17 s, to 
328±137 s). In these cells, the interburst period was reduced (from 64±26 to 61±18 s); the 
activity quotient was increased from 0.6±0.1 to 0.7±0.1, and the intraburst frequency was 
increased from 6.6±0.8 to 7.2±0.7 spikes/s. 
Eight of ten vasopressin cells in fasted rats and nine of sixteen vasopressin cells in 
non-fasted rats increased their activity by more than 10% after i.v. insulin, and the mean 
response of all vasopressin cells tested was greater in fasted rats than in non-fasted rats, but 
this did not reach statistical significance (Mann-Whitney U test, P=0.63). 
 
Hazard functions 
In oxytocin cells, the hazard functions conformed to the profile previously reported as 
typical of oxytocin cells, reflecting a prolonged post-spike refractoriness of 30-50 ms 
followed by a stable plateau of excitability(42). Insulin did not affect the duration of the post-
spike refractoriness but elevated the plateau level of excitability (Fig. 2E). 
In vasopressin cells, the hazard functions also conformed to the profile previously 
reported as typical of vasopressin cells, reflecting a post-spike refractoriness of 20-50 ms 
followed by a period of hyperexcitability (reflecting a depolarising afterpotential) before 
reaching a stable plateau of excitability(42). Insulin did not affect the duration of the post-
spike refractoriness or the plateau level of excitability but enhanced the post-spike 
hyperexcitability (Fig.2F). 
 
Effect of i.v. insulin on blood glucose and spike activity of SON neurones 
At the time of recording from SON neurones (~ 3h after i.p. anaesthesia), blood 
glucose concentrations were 12.7±0.8 mmol/l in fasted rats and 19.9±2.0 mmol/l in non-
fasted rats. In both groups, plasma glucose levels were unchanged after injections of vehicle 
(0.9% saline) but fell after i.v. insulin, reaching a nadir after 60 min (Fig.3A; Two-way 
ANOVA; interaction F (18, 162) = 6.69; time, F (6, 162) = 20.11; treatment, F (3, 27) = 10.8; 
subject, F (27, 162) = 12.9, all P<0.001). 
To test whether the activation of SON neurones by i.v insulin reflected the reduction 
in plasma glucose concentrations, we injected insulin to activate SON neurones in ten fasted 
rats and then gave i.v. glucose to restore basal glucose concentrations (Fig.3B; one-way 
ANOVA,  F (1.936, 17.42) = 9.275 P=0.002). 
We tested five oxytocin cells in four of these rats. The mean basal firing rate (1.9(0.3-
4.4)±0.7 spikes/s) increased by 1.1(0.4-1.7)±0.2 spikes/s after insulin. After i.v. glucose, the 
firing rate continued to increase reaching a final mean change of 1.6(1.0-3.0)±0.4 spikes/s 
(Fig.3C; Wilcoxon matched-pairs signed rank test, P=0.06). 
We tested six vasopressin cells (of which one fired phasically) in six of the rats (one 
of the vasopressin cells was recorded simultaneously with an oxytocin cell). The mean basal 
firing rate (5.2(3.4-6.9)±0.6 spikes/s) increased by 1.2(0.6-2.4)±0.3 spikes/s after insulin. 
After glucose, the rate did not change significantly (final mean change 1.3(0.6-2.3)±0.3 
spikes/s; Fig.3D; Wilcoxon matched-pairs signed rank test, P=0.8). 
Thus, in the case of both oxytocin cells and vasopressin cells, responses to insulin 
were unaffected by i.v injections of glucose. 
 
Blockade of central InsRs before i.v. insulin 
To test whether the activation of SON neurones by insulin involves brain InsRs, we studied 
the effect of central administration of S961 on the responses (Fig.4). At 30-min after insulin 
injection, the blood glucose concentration in rats pretreated with i.c.v. S961 had fallen by 
7.4±1.0 mmol/l, similar to the fall in fasted rats injected with insulin alone (7.4±0.9 mmol/l), 
indicating that the central injection of S961had no peripheral effect within this time (Fig.4C; 
repeated measures ANOVA, F(2, 28) = 49.8; P<0.0001). 
The firing rate of eight oxytocin cells (2.8(1.3-5.3)±0.5 spikes/s; from 8 rats) was not 
significantly affected by S961 (change 0.2(-0.7-1.3)±0.2 spikes/s; Wilcoxon signed rank test, 
P=0.54). However, i.v. insulin had no effect in rats pretreated with S961 (change: -0.01(-0.4-
0.3)±0.1 spikes/s after i.v. insulin; Wilcoxon signed rank test, P=1.0, Fig.4A). 
Similarly the firing rate of eleven vasopressin cells (5.7(3.7-7.7)±0.3 spikes/s; 6 continuous- 
and 5 phasic cells in 10 rats) was not significantly affected by S961 (change 0.16 (-2.3-
1.7)±0.3 spikes/s; Wilcoxon signed rank test, P=0.37). After i.v. insulin, their firing rate 
increased by 0.5(-1.5-3.3)±0.4 spikes/s, but this was not significant (Wilcoxon signed rank 
test, P=0.24; Fig.4B). 
Thus central administration of S961 blocked the responsiveness of oxytocin cells to 
systemic administration of insulin but had no significant effect on vasopressin cells. 
 
Effect of blockade of central InsRs on oxytocin spike activity induced by SCM gavage 
Gavage of food rich in sugars, but not fat, results in a rise of blood glucose and insulin 
plasma concentration and a progressive increase in the electrical activity of oxytocin cells 
(37). Here, we tested whether this involves brain InsRs. 
Both vehicle- and S961-injected rats exhibited a significant increase in both blood 
glucose concentration and plasma insulin concentration following SCM gavage (Fig.5A) with 
no significant differences between groups (glucose: two way-ANOVA for repeated measures: 
interaction, F(3, 24) = 0.7769, P=0.52; time, F(3, 24) = 44.41, P < 0.0001; treatment, F(1, 8) 
= 0.4899, P = 0.5038; subjects, F(8, 24) = 29.9, P < 0.0001; insulin: interaction, F(3, 18) = 
0.083, P=0.97; interaction, F(3, 18) = 10.17, P=0.0004; treatment, F(1, 6) = 0.18, P=0.7; 
subjects, F(6, 18) = 2.1, P=0.1). 
In vehicle-injected rats, as expected (37), SON oxytocin cells were progressively 
activated during SCM gavage. The firing rate of five oxytocin cells (from four rats) increased 
from 2.5 (1.3-3.1)±0.3 spikes/s.by 1.1(0.7-1.5)±0.1 spikes/s over during 60 min of gavage 
(Fig.5B). By contrast, in rats injected with S961, oxytocin cells did not respond to SCM 
gavage (Fig. 5C). The firing rate of five oxytocin cells (from five rats) increased from 
3.2(1.4-5.4)±0.8 spikes/s by -0.1 (-1.0-0.7)±0.3 spikes/s during 60 min of gavage. This 




Recently, the role of oxytocin cells in metabolic regulation has attracted increasing 
attention. Most attention has been given to the oxytocin cells of the PVN, as these include a 
small population of parvocellular neurones that project to the dorsal vagal complex and to the 
spinal cord, where their actions include effects on gastric reflexes, energy intake and 
thermogenesis (23, 43, 44). Until relatively recently, the magnocellular oxytocin cells, which 
comprise most of the oxytocin cells in the PVN and all those in the SON, were thought to 
have few central projections. However, these neurones, which all project axons to the 
posterior pituitary, also release large amounts of oxytocin within the brain from their 
dendrites. This dendritic release is likely to have important effects at relatively local sites, 
including the amygdala and the ventromedial nucleus of the hypothalamus where abundant 
oxytocin receptors are expressed but which contain only sparse oxytocin fibres (23, 45). In 
addition, it has recently become apparent that many magnocellular neurones have extensive 
axonal projections to diverse brain regions, including notably to the nucleus accumbens.(46) 
In the present study, systemic administration of insulin increased the electrical activity 
of both oxytocin and vasopressin SON cells, consistent with previous reports in humans and 
rats that insulin increases secretion of oxytocin and vasopressin (47-49). 
As originally conceived in the design of the present experiments, the dose and route 
of insulin administration followed the conventional design of insulin tolerance tests (50), to 
produce an acute maintained hypoglycaemia. This bolus injection raises peripheral insulin 
concentrations above the normal physiological range, which are then rapidly cleared. The 
evolution of oxytocin cell activity after insulin injections thus mirrored neither the changes in 
plasma glucose nor the expected changes in peripheral insulin concentration. Insulin crosses 
the blood-brain barrier by an active transport mechanism that is saturated: at least 50% of 
maximal transport capacity is reached at euglycemic levels of plasma insulin, thus 
supraphysiological levels of insulin in the plasma have little additional effect on insulin 
penetration into the brain beyond that seen at high physiological levels (1, 51). Thus the 
expected evolution of CNS insulin following i.v. bolus injection is a progressive rise while 
peripheral levels are elevated above normal levels – possibly explaining the progressive rise 
in oxytocin cell activity. 
Brain InsRs play an important role in the control of energy balance as shown by 
selective genetically-induced decreased expression of brain InsRs which is linked to a 
peripheral metabolic alterations, including increased food intake, fat, and body weight, as 
well as increased glucose and insulin resistance in rodents (52, 53). Moreover, injection of 
the InsR antagonist S961 into the ventromedial nucleus increases blood glucose concentration 
in rats (54). In the present study, central administration of S916 prevented the insulin-induced 
responses in all oxytocin cells, indicating that systemic insulin penetrates into the brain to 
activate SON neurones by actions on central InsRs. The central administration of S916 
produced a non-significant increase in plasma glucose concentrations consistent with its 
reported effects in the ventromedial nucleus (54), and did not affect the effect of systemically 
applied insulin on plasma glucose levels, indicating that, at this dose and by this route, it did 
not block systemic effects of exogenous insulin. 
In humans, glucose, but not fructose, infusion has been shown to prevent oxytocin and 
vasopressin release by insulin-induced hypoglycaemia (55).In this study, we infused bolus 
injections of glucose solution to approximately clamp circulating glucose concentrations after 
i.v. insulin. Once the firing response was triggered, neither oxytocin nor vasopressin cells 
reduced their spike activity after glucose injections. 
In non-fasted rats, which exhibited a more pronounced hyperglycaemia than fasted 
rats, the responses of oxytocin cells were less prominent than in fasted rats. This may reflect 
InsR desensitisation in oxytocin cells, similarly to that shown in skeletal muscle in vivo (56) 
and fibroblasts in vitro (57), where acute exposition to high glucose concentration reduced 
insulin-stimulated glucose uptake and impaired InsR intracellular signalling, respectively. 
Alternatively, as in fasted animals blood glucose concentrations fell following insulin 
administration to concentrations lower than immediately after anaesthesia, this might 
stimulate the hypothalamo-pituitary-adrenal (HPA) as occurs in the insulin tolerance test 
(55), potentiating the release of oxytocin (and vasopressin). 
A recent study (17) raised the question about the capacity of SON neurones to 
respond to insulin administration since insulin given i.c.v. induced an increase in Fos 
expression after 90-min in 13 % of the PVN, but not SON, oxytocin cells compared to control 
mice. Nevertheless, SON neurones appear to be intrinsically sensitive to insulin and glucose 
as they express InsR (12-14) and also the enzyme glucokinase (58), a marker for glucose 
sensing. Moreover, vasopressin and oxytocin are released from SON explants in the presence 
of medium containing glucose and insulin (16). Although Fos protein has been widely used 
as a marker for neuronal activation, its lack of expression does not necessarily exclude 
changes in neural activity as observed in some conditions, and increased spike activity is not 
invariably linked to Fos expression (59, 60). It seems that insulin might not induce the 
expected rapid expression of Fos (i.e. 60-90 min) as Griffond et al. reported that at 1 h after 
insulin i.p. (20 mg/kg), there was little expression of Fos in PVN oxytocin cells(15). 
A limitation of this study is that it involved urethane-anesthetised rats. Urethane has 
long been the anaesthetic of choice for SON electrophysiological recordings, as it provides a 
deep long-lasting stable anaesthesia compatible with transpharyngeal surgery without 
affecting the physiological responses of SON neurones (40). However, urethane raises blood 
glucose concentrations (61, 62) by increasing sympathetic tone (63) and consequently 
increasing gluconeogenesis. Thus, blood glucose concentrations in both non-fasted and fasted 
anaesthetised rats were higher than in conscious Sprague-Dawley rats (64). However they 
were lower in fasted rats than in non-fasted rats, and changed in the expected manner in 
response to i.v. insulin. 
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Figure 1. Identification of SON neurons. (A) Voltage trace showing the electrical 
stimulation (red stimulus artefact; 0 ms) of the pituitary stalk which evokes an antidromic 
spike travelling to the soma of SON neurones at a constant latency (~10 ms) in each of two 
neurons (red spikes), and spike collision occurring when an spontaneous orthodromically 
traveling spike (black spike) encounters an antidromic spike (centre and right panels) 
extinguishing it. (B) Raw voltage trace of a double recording showing the spike activity of a 
continuous- (black large spikes) and a phasic-firing (red short spikes exhibiting intermittent 
periods of activity) vasopressin cell. (C, D) Typical ISI histogram (frequency of time 
distributions between (two) occurring spikes) over 10-min and corresponding hazard function 
of the basal spontaneous activity of an (C) oxytocin cell, and (D) vasopressin cell. (E,F) 
Pharmacological identification of SON neurones. Raw voltage trace (upper panel) and firing 
rate (spikes in 10s bins; lower panel) of an (E) oxytocin, and (F) vasopressin cell exhibiting 
transient excitation and inhibition respectively in response to i.v. CCK (20 µg/kg). 
 
Figure 2. Effect of i.v. insulin on SON neurones in fasted rats.  
(A) Representative example of the firing rate of an identified oxytocin cell (in 30-s bins; 
upper panel and instantaneous frequency plot below) in response to an i.v. injection of 
insulin. The dashed line indicates the mean basal firing rate. (B) ISI distribution and average 
waveform (lower panels) over 10-min period during baseline (left, corresponding to the solid 
line in A) and maximal neuronal response (right, corresponding to the dotted line in A) of the 
neurone shown in A. (C). Average responses (mean changes from baseline ± SEM) of ten 
oxytocin cells in fasted rats (black) and ten in non-fasted rats (white) to i.v. insulin. (D) 
Average responses of 16 vasopressin cells in fasted rats (black) and 16 in non-fasted rats 
(white) to i.v. insulin. (E) Mean (SEM) Hazard functions of the ten oxytocin cells in fasted 
rats before (closed symbols) and after insulin (open symbols). (F). Mean (SEM) Hazard 
functions of eight vasopressin cells in fasted rats before (closed symbols) and after insulin 
(open symbols; two cells excluded as the basal firing rates were too low to construct hazard 
functions). 
 
Figure 3. Effect of i.v. glucose infusion in insulin-responsive neurones in fasted rats.  
(A) Blood glucose concentrations were lowered after i.v. insulin, but not i.v. vehicle, in fasted 
and non-fasted rats (*P < 0.05, Two-way ANOVA followed by Bonferroni post hoc test). (B) 
Blood glucose concentrations after i.v. insulin and after i.v. insulin, and 5% glucose solution 
injections (arrows: as required) of all 10 rats where neuronal activity was recorded. After 30-
min of i.v. insulin, the glucose concentration was significantly lower compared to all other 
blood samples (one-way ANOVA for repeated measures; ***P<0.001, Bonferroni post hoc) 
with no significant differences between other samples. (B) Blood glucose concentrations after 
i.v. insulin, and 5% glucose solution injections (arrows: 400 µl, *300 µl, *100 µl; * if 
required) of all animals (n=10) where neural activity was recorded. (C,D) After insulin, no 
significant differences in firing rate of (C) oxytocin, and (D) vasopressin cells in glucose-
treated rats were detected when compared to non-glucose treated fasted rats. Data are means 
± SEM. 
 
Figure 4. Effect of central InsR blockade on neuronal responses following i.v. insulin in 
fasted rats.  
(A,B) Administration of S961 (1 nmole i.c.v. ) blocked the increase in firing rate (in 10-min 
bins) induced by i.v. insulin in (A) oxytocin, but not (B) vasopressin cells when compared to 
fasted rats injected with i.v. insulin alone (Figure 3). (C) Blood glucose concentration tended 
(P = 0.13) to increase 15 min after of i.c.v. InsR antagonist administration, insulin i.v. 
significantly lowered the blood glucose concentration after 30-min compared to basal, and 
InsR antagonist blood samples (***P<0.001, One-way ANOVA for repeated measurements, 
followed by Bonferroni post hoc test; n=15), in brackets, times since basal. Data are means ± 
SEM. 
 
Figure 5. Effect of central InsR blockade on SCM-induced increase in firing rate in 
oxytocin cells.  
(A) Gavage of 5 ml of SCM significantly increased blood glucose concentrations (left panel; 
P<0.05, Two-way ANOVA followed by Bonferroni post hoc compared to baseline) and 
plasma insulin (right panel) in both i.c.v. vehicle- and S961-treated rats with no significant 
differences between groups. (B) Representative examples showing the increase in firing rate 
(in 30-s bins) induced by SCM gavage (5 ml) in a vehicle-injected rat (upper panel), and 
blockade of SCM-induced response in an. S961-injected rat. (C) Mean change (± S.E.M.) in 
firing rate over 60 min from all oxytocin cells recorded in i.c.v. vehicle- and S961-injected 
rats gavaged with SCM (*P<0.05 Mann-Whitney test). (D) The change in firing rate (in 10-
min bins) was significantly different between groups after 30-min since the beginning of 
SCM gavage. Data are means  ± SEM. 
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